Columbia and HCA divests as HealthSouth buys ASC
This article was originally published in Clinica
Executive Summary
Columbia/HCA has cancelled hospital building and plans to sell most of the recently-acquired Value Health business. At the same time, HealthSouth, which has shown interest in acquiring some or all of the beleaguered healthcare group, will pay $180 million in cash and debt assumption for a chain of 29 surgery centres. Columbia recently paid $1.1 billion for Value Health and now intends to sell its pharmacy benefits management company which represents around 80% of Value Health's $1.8 billion turnover. Columbia will also shed the managed care company specialising in behavioural therapy and the information technology-based disease management division.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.